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Background
The DALIA trial tested the hypothesis that immuniza-
tion with HIV peptide loaded Dendritic Cells (DC) may
improve HIV immune responses and help to contain
viral replication.
Methods
19 pts with CD4 >500 cells/m3 and HIV RNA <50 cp/ml
under HAART received at W0, 4, 8 and 12 ex-vivo gener-
ated IFN-a DC loaded with HIV-1 lipopeptides. Analytical
treatment interruption (ATI) was conducted from W24.
HAART resumption regardless of the reason and CD4
<350 cells/mm3 (or <25%) were considered as end points.
HIV-specific immunity was evaluated at baseline, W16,
and W48 using: i) ex vivo IFN-g ELISPOT; ii) intra cellular
staining; iii) multiplex analysis. PBMCs were stimulated
with HIV peptide pools. Student t-test and Wilcoxon
signed-rank tests were used with estimation of the False
Discovery Rates (FDR) for controlling test multiplicity.
Results
Vaccine regimen was well tolerated. Following ATI, all pts
experienced a viral rebound in 14 days in median (IQR 8-
27). Median highest observed VL (peak) was 5 (4.28-5.23)
log10 cp/ml. Three patients resumed HAART and eight
had CD4 <350 cells/mm3. Median (IQR) SFU/106 PBMC
rose from 186 (140-670) at baseline to 761 (470-1154) and
1878 (1102-4443) at W16 and 48, respectively. At the
same time points the breadth of the response (nb of pep-
tide pools) increased from 1 (1-3) to 4 (2-5) (P=.009) and
6 (3-7) (P=.008). % of polyfunctional CD4+ (> 2 cytokines
among: IFN-g,TNF-a,IL-2) increased from 0.026% (w-4)
to 0.32% (w16) (P=.002). Respective % of CD8+ were
0.26% and 0.35% (P=.005). Production of IL-2, IFN-g,
IL-21, IL-13, IL-17 increased significantly at W16
(FDR<.05). An inverse correlation was found between the
peak of VL and % of polyfunctional CD4+ (r=-0.63,
FDR=.007), production of IL-2 (r=-0.67, FDR=.006), IFN-g
(r=-0.58, FDR=.01), IL-21 (r=-0.66, FDR=0.006) and IL-13
(r=-0.78, FDR=.001).
Conclusion
DC vaccination elicited polyfunctional HIV-specific
responses associated with a reduced peak viral load fol-
lowing ATI.
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